AstraZeneca bulks up Imfinzi's prowess with FDA nod in bladder cancer around surgery
Imfinzi is the first immunotherapy cleared in the U.S. to treat muscle-invasive bladder cancer patients before and after bladder removal surgery, making for a new treatment option in a disease with high rates of recurrence.
Imfinzi is the first immunotherapy cleared in the U.S. to treat muscle-invasive bladder cancer patients before and after bladder removal surgery, making for a new treatment option in a disease with high rates of recurrence.
